SOURCE: IDenta Corp.

April 10, 2007 10:30 ET

New Patents, Products, U.S. Marketing Mission Top Spring Agenda for International Drug and Explosive Detection Firm IDenta

JERUSALEM -- (MARKET WIRE) -- April 10, 2007 -- IDenta Corp. (PINKSHEETS: IDTA) released a memorandum today detailing a number of significant activities the company will be undertaking in the coming months. The memo lists activities with the government of France, a U.S. visit by IDenta's CEO along with its Chief Scientist in early May, the development of a drug detector for morphine, the completion of testing for two new drug detectors, and applications for two new U.S. patents.

"It is hard to prioritize the value of these business activities, but do I feel that this mission to the U.S. may be our most important in a long time," said Yaacov Shoham, IDTA CEO. "Our marketing channels in the U.S. are beginning to report sales of drug detectors, as well as a growing interest in our IDenta Alert explosive detectors. We have scheduled high-level meetings in each of the cities we are visiting, and expect to make some very important announcements following this trip."

Significant company activities for the next three months include:

1. United States Marketing Mission -- the current schedule includes appointments with company representatives and law enforcement agencies in Orlando, Atlanta, Los Angeles and New York.

2. Canada -- A visit to Toronto to finalize an agreement for product sales and representation.

3. GHB (a.k.a. date rape drugs) detection kits will soon be in production. The company believes there may be a significant consumer market for this detector because of the easy and inexpensive ability to detect the presence of illegal substances in substances such as alcoholic drinks served in bars and night clubs.

The Ketamine drug detector will also soon be in production.

4. IDenta is expecting to receive patents for several new products including the GHB kit (drug testing kit) and for TATP (explosive identifiers). Company testing of the TATP kit indicates it may be the most advanced, reliable explosive detector kit currently on the market.

5. The French Interior Minister has asked IDenta to develop a new drug detector for morphine.

6. The Marseille Laboratory in France is currently testing IDenta Alert explosive identifiers against other competing products. Indications from the company's representatives in France, IBTEC, indicate that the final report will be very positive.

Any publication or law enforcement agency interested in speaking directly with Mr. Shoham while he is in the U.S. may call 800-316-9437 or email him at fpi@drugsdetector.com.

A teleconference for the press and the investment community has tentatively been scheduled for May 1st at 9:30 a.m. eastern daylight time.

ABOUT IDENTA

Since 2003, IDenta Corporation has become recognized as a worldwide leader in the development of proprietary on-site drug detection kits and most recently explosive detection kits. IDenta develops, manufactures and distributes products for the both professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's business plan and product line may be found at www.identa.biz and www.drugsdetector.com.

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact Information

  • Contact:

    For Investor Relations, lobbying interests or information concerning
    IDenta's products internationally contact:

    Yaacov Shoham
    IDenta Corp.
    CEO
    Tel: +972-52-6554487
    +972-8-9716874
    Fax: +972-8-9716875
    fpi@drugsdetector.com

    For Investor Relations in the United States contact:
    Randy Jacobs
    U.S. Corporate Spokesman
    IDentaNews@sitcomllc.com
    1-800-316-9437